Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...

Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our ...

Don't Miss our Black Friday Offers: Terence Flynn’s rating is based on the performance and potential of Eli Lilly & Co’s key products, particularly Mounjaro and Zepbound. These medications ...

Eli Lilly’s new products (products launched since 2022 like Ebglyss, Jaypirca, Mounjaro, Kisunla, Omvoh and Zepbound) contributed $4.51 billion to revenues, led by Mounjaro and Zepbound.

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows The FDA approved tirzepatide as Mounjaro for adults with type 2 ...

The anti-obesity drug market has expanded in recent years with FDA approval for a new class of drugs like Eli Lilly's Zepbound, which can cost close to $1,000 per month for those paying out-of-pocket.